Cargando…
Targeted lung denervation modulates the mucosal epithelial transcriptome in COPD
This study shows that TLD reduces airway epithelial expression of genes related to acetylcholine processing and airway inflammation, which may help to elucidate the mechanism for its effect of reducing severe exacerbations in COPD https://bit.ly/3dWcqZk
Autores principales: | Srikanthan, Karthi, Kistemaker, Loes, Slebos, Dirk-Jan, Gesierich, Wolfgang, Darwiche, Kaid, Bonta, Peter, Deslee, Gaetan, Shah, Pallav, Gosens, Reinoud |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793243/ https://www.ncbi.nlm.nih.gov/pubmed/36578630 http://dx.doi.org/10.1183/23120541.00146-2022 |
Ejemplares similares
-
Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial
por: Slebos, Dirk-Jan, et al.
Publicado: (2019) -
Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2
por: Valipour, Arschang, et al.
Publicado: (2020) -
Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
por: Christophe, Pison, et al.
Publicado: (2021) -
Correction to: Safety of denervation following targeted lung denervation therapy for COPD: AIRFLOW-1 3-year outcomes
por: Pison, Christophe, et al.
Publicado: (2021) -
Long-term safety of bilateral targeted lung denervation in patients with COPD
por: Valipour, Arschang, et al.
Publicado: (2018)